Acute on Chronic Liver Failure (ACLF) Market is Anticipated to Witness High Growth Owing to Rising Prevalence of Liver Diseases

Acute on chronic liver failure (ACLF) refers to an acute deterioration of pre-existing chronic liver disease, usually related to a precipitating event and associated with increased mortality risk. It represents a syndrome with acute decompensation of cirrhosis characterized by jaundice, ascites, hepatic encephalopathy or variceal bleeding. ACLF includes acute deterioration of liver function in a patient with chronic liver disease, generally cirrhosis that results in organ failure and high short-term mortality. The main causes of ACLF include alcohol, viral hepatitis, autoimmune liver disease and drug-induced liver injury.

The Global Acute on Chronic Liver Failure Market is estimated to be valued at US$ 4.2 Bn in 2024 and is expected to exhibit a CAGR of 5.3% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the acute on chronic liver failure (ACLF) are Promethera Biosciences, Beijing Continent Pharmaceutical Co, Ltd, Cellaion SA, and Versantis. Promethera Biosciences is developing a cell therapy product HepaStem for the treatment of ACLF. Beijing Continent Pharmaceutical Co, Ltd is research on drug Niuchangmycin for ACLF treatment.

The key opportunities in the ACLF market are development of cell-based therapies and regenerative medicines for ACLF treatment. Cell therapies like HepaStem and regenerative medicines can aid in liver regeneration and reduce mortality. There is lack of approved pharmacological treatment options for ACLF, representing significant market opportunity.

Globally, companies are focusing on expanding presence in Asia Pacific and Latin America for ACLF treatment. Asia Pacific is a major market owing to presence of large patient pool of chronic liver disease in countries like China and India. Latin America is also witnessing rising burden of chronic liver disease and ACLF, offering scope for market players. Collaboration with local players can help giants penetrate untapped markets.

Market drivers: Rising prevalence of chronic liver disease and risk factors like alcohol abuse, HCV/HBV infections are majorly driving the ACLF market. According to WHO, viral hepatitis affects approximately 325 million people globally. Advanced research on regenerative medicines and cell therapies is also supporting market growth.

Market restrain: High cost of cell therapies and lack of reimbursement are significant challenges. Long development cycles and regulatory hurdles for new drugs delay market access. Variations in definitions, diagnosis criteria and lack of approved standards also hinder ACLF treatment to some extent.

Segment Analysis

There are primarily two major segments for ACLF market namely, hospital pharmacy and retail pharmacy. The hospital pharmacy segment currently dominates the ACLF market mainly due to higher number of patients requiring immediate treatment and management of the disease condition in hospitals. Most patients suffering from ACLF require continual monitoring and care in hospitals involving the use of drugs, equipment and other support. This segment is expected to continue its dominance over the forecast period owing to the critical nature of disease and associated treatment procedures carried out in hospitals.

Global Analysis

Regionally, North America is projected to dominate the global ACLF market during the forecast period. This is majorly attributed to factors such as rising health awareness, increasing research activities for novel drug development, presence of advanced healthcare infrastructure and facilities for treatment of chronic liver diseases. Additionally, growing expenditure on healthcare sector in the US and Canada is also boosting the market growth. However, Asia Pacific region is anticipated to witness highest growth rate over the coming years primarily due to increasing incidences of liver diseases, growing obese population, changing lifestyle habits and improving healthcare amenities in emerging economies like India and China. Latin America and Middle East & Africa are also expected to show considerable growth owing to rising government initiatives to enhance healthcare access across the regions.

Get more insight on this topic : https://medium.com/@jacksmithss0909/the-acute-on-chronic-liver-failure-market-expanding-at-a-cagr-of-5-3-c4d0c191951c